Adaptive Biotechnologies Corp Total Liabilities
Adaptive Biotechnologies Corp total liabilities. Based on the latest financial reports, Adaptive Biotechnologies Corp (ADPT) has total liabilities worth $287.74 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Adaptive Biotechnologies Corp liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Adaptive Biotechnologies Corp (2017–2025)
Total liabilities of Adaptive Biotechnologies Corp from 2017 to 2025. This chart illustrates how Adaptive Biotechnologies Corp's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Adaptive Biotechnologies Corp's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Adaptive Biotechnologies Corp Competitors by Total Liabilities
The table below lists competitors of Adaptive Biotechnologies Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Seabridge Gold Inc.
TO:SEA
|
Canada | CA$650.17 Million |
|
Top Choice Medical Investment Co Inc
SHG:600763
|
China | CN¥1.45 Billion |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
Germany | €403.87 Billion |
|
Alsea S.A.B. de C.V
MX:ALSEA
|
Mexico | MX$70.00 Billion |
|
Haemonetics Corporation
NYSE:HAE
|
USA | $1.60 Billion |
|
Legend Holdings Corporation
F:1PC
|
Germany | €665.71 Billion |
|
Hamilton Insurance Group, Ltd.
NYSE:HG
|
USA | $7.11 Billion |
|
Cecep Environmental Protection Equipment Co Ltd
SHE:300140
|
China | CN¥15.20 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Adaptive Biotechnologies Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Adaptive Biotechnologies Corp balance sheet assets.
Liquidity & Leverage Metrics
Adaptive Biotechnologies Corp Total Liabilities Ratios Explained
Adaptive Biotechnologies Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adaptive Biotechnologies Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adaptive Biotechnologies Corp (2017–2025)
The table below shows the annual total liabilities of Adaptive Biotechnologies Corp from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $287.74 Million | -14.59% |
| 2024-12-31 | $336.89 Million | -4.52% |
| 2023-12-31 | $352.86 Million | -10.10% |
| 2022-12-31 | $392.52 Million | +22.95% |
| 2021-12-31 | $319.24 Million | -14.45% |
| 2020-12-31 | $373.15 Million | +9.34% |
| 2019-12-31 | $341.26 Million | -42.24% |
| 2018-12-31 | $590.80 Million | +0.63% |
| 2017-12-31 | $587.11 Million | -- |
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diag… Read more